Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
43.45
+0.42 (0.98%)
Aug 4, 2025, 4:00 PM - Market closed
ShockWave Medical Employees
Ionis Pharmaceuticals had 1,069 employees as of December 31, 2024. The number of employees increased by 142 or 15.32% compared to the previous year.
Employees
1,069
Change (1Y)
142
Growth (1Y)
15.32%
Revenue / Employee
$883,115
Profits / Employee
-$250,904
Market Cap
6.93B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,069 | 142 | 15.32% |
| Dec 31, 2023 | 927 | 131 | 16.46% |
| Dec 31, 2022 | 796 | 136 | 20.61% |
| Dec 31, 2021 | 660 | -97 | -12.81% |
| Dec 31, 2020 | 757 | -60 | -7.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IONS News
- 5 days ago - Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug - Benzinga
- 5 days ago - Ionis reports second quarter 2025 financial results and highlights progress on key programs - Business Wire
- 10 days ago - TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS) - Business Wire
- 14 days ago - Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice - Business Wire
- 19 days ago - Ionis to hold second quarter 2025 financial results webcast - Business Wire
- 5 weeks ago - Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight - Seeking Alpha
- 5 weeks ago - Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results - Business Wire